Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS9642735 B2
Publication typeGrant
Application numberUS 11/602,620
Publication date9 May 2017
Filing date20 Nov 2006
Priority date28 Jul 2003
Also published asCA2576476A1, CA2576476C, EP1781183A2, EP1781183A4, EP1781183B1, US9498366, US20050055039, US20070135831, WO2006020370A2, WO2006020370A3
Publication number11602620, 602620, US 9642735 B2, US 9642735B2, US-B2-9642735, US9642735 B2, US9642735B2
InventorsDaniel R. BURNETT
Original AssigneeBaronova, Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Pyloric valve corking device
US 9642735 B2
Abstract
Pyloric valve corking devices are disclosed herein that generally include an occluding member, expanding from a first configuration to a larger second configuration, and a bridging member extending from the occluding member. The bridging member has a length that is adapted to pass at least partially through the gastric opening, so to enable the occluding member to obstruct the gastric opening, and that is also adapted to permit the occluding member to intermittently move relative to the gastric opening. A second occluding member may be attached to the distal end of the bridging member. The reduction in flow of gastric contents into the duodenum can be actively regulated using a pump or valve, or can be passively regulated with movements of the occluding device.
Images(16)
Previous page
Next page
Claims(73)
What is claimed is:
1. A device for obstructing a gastric opening, comprising:
an occluding member having an inflated state and an uninflated state, wherein an outer diameter of the occluding member is configured to expand when fluid enters the occluding member and the occluding member is inflated from the uninflated state to the inflated state after deployment, wherein the occluding member is further adapted to collapse from the inflated state back to the uninflated state for removal and wherein the inflated state of the occluding member is a radially expanded shape which inhibits permanent obstruction of the gastric opening;
a bridging member extending from the occluding member, wherein the bridging member has a length adapted to pass at least partially through the gastric opening and to enable the occluding member to obstruct the gastric opening, and wherein the length further maintains a diameter which is sufficient to permit the occluding member and the bridging member to intermittently move relative to the gastric opening without obstructing the gastric opening, wherein the bridging member maintains its shape prior to and after deployment through the gastric opening; and
a second member connected to a distal end of the bridging member, where the second member has a diameter which is relatively larger than the bridging member and smaller than the outer diameter of the occluding member when the occluding member is in the inflated state.
2. The device of claim 1, wherein the occluding member is adapted to expand from the uninflated state during delivery to the inflated state during placement within the gastric opening.
3. The device of claim 1, further comprising a fluid for inflating the occluding member.
4. The device of claim 3, wherein the fluid comprises a liquid or gas.
5. The device of claim 1, further comprising a visible dye or marker infused within the occluding member.
6. The device of claim 1, wherein the occluding member is comprised of a distensible material.
7. The device of claim 1, wherein the occluding member is comprised of a material visually distinct from bodily tissue.
8. The device of claim 1, further comprising a biodegradable covering over the occluding member, the covering being adapted to degrade upon insertion within a gastric lumen.
9. The device of claim 1, wherein the occluding member comprises an expandable foam.
10. The device of claim 1, wherein the occluding member comprises an expandable hydrogel.
11. The device of claim 1, wherein the occluding member comprises an expandable scaffolding.
12. The device of claim 1, wherein the occluding member defines a cross-sectional shape along a longitudinal axis, the shape being selected from the group consisting of circles, ellipses, triangles, diamonds, rectangles, squares, and combinations thereof.
13. The device of claim 1, wherein the second member comprises a weighted member.
14. The device of claim 13, wherein the second occluding member comprises an expandable foam.
15. The device of claim 13, wherein the second occluding member comprises an expandable hydrogel.
16. The device of claim 13, wherein the second member comprises an expandable scaffolding.
17. The device of claim 1, wherein the second member and the occluding member are in fluid communication through the bridging member.
18. The device of claim 1, wherein the second member is inflatable.
19. The device of claim 18, further comprising a visible dye or marker within the second member.
20. The device of claim 18, wherein the second member is comprised of a distensible material.
21. The device of claim 18, wherein the second member is comprised of a material visually distinct from bodily tissue.
22. The device of claim 18 further comprising a biodegradable covering over the second member, the covering being adapted to degrade upon insertion within a gastric lumen.
23. The device of claim 22, wherein the occluding member also comprises a biodegradable covering thereon, the covering over the second member being adapted to degrade at a rate different from a degradation rate of the covering over the occluding member.
24. The device of claim 22, wherein the occluding member also comprises a biodegradable covering thereon, the covering over the second member being adapted to degrade at a rate similar to a degradation rate of the covering over the occluding member.
25. The device of claim 1, wherein the second member is further adapted to collapse.
26. The device of claim 1, wherein the bridging member has a length of at least 2 cm.
27. The device of claim 1, wherein the bridging member has a diameter which is less than a diameter of the occluding member in the inflated state.
28. The device of claim 1, wherein the bridging member defines a lumen therethrough with a seal adapted to close the lumen.
29. The device of claim 1, wherein the bridging member comprises a weight.
30. The device of claim 1, wherein the bridging member is adapted to be positioned through the gastric opening and remain within a gastric lumen.
31. The device of claim 1, wherein the length of the bridging member is tapered.
32. The device of claim 1, wherein the bridging member defines a lumen therethrough.
33. The device of claim 32, further comprising a valve positioned within the lumen.
34. The device of claim 33, wherein the valve comprises a unidirectional valve.
35. The device of claim 33, wherein the valve comprises a passively-controlled valve.
36. The device of claim 33, wherein the valve comprises an actively-controlled valve.
37. The device of claim 1, further comprising at least one inflation port defined upon the occluding member.
38. The device of claim 37, wherein the inflation port is self-sealing.
39. The device of claim 37, wherein the inflation port is comprised of a metallic material.
40. The device of claim 39, wherein the metallic material is magnetic.
41. A system for intermittently obstructing a gastric opening, comprising:
a first occluding member and a second member, wherein the first occluding member has an inflated state and an uninflated state, wherein an outer diameter of the first occluding member is configured to expand when fluid enters the occluding member and the occluding member is inflated from the uninflated state to the inflated state after deployment, wherein the first occluding member is further adapted to collapse from the inflated state back to the uninflated state for removal and wherein the inflated state of the first occluding member defines a radially expanded shape which inhibits permanent obstruction of the gastric opening; and
a bridging member extending between the first occluding member and the second member,
wherein the bridging member has a flexible length adapted to pass through the gastric opening and to enable the first occluding member to obstruct the gastric opening and to be retained by the second member, wherein the bridging member maintains its shape prior to and after deployment, and wherein the bridging member further maintains a diameter which is sufficient to permit the first occluding member and the bridging member to intermittently move relative to the gastric opening without obstructing the gastric opening, and
wherein the second member is attached to a distal end of the bridging member and has a diameter which is larger than the diameter of the bridging member and smaller than the outer diameter of the first occluding member when the first occluding member is in the inflated state.
42. The system of claim 41, wherein the first occluding member is adapted to expand from the uninflated state during delivery to the inflated state during placement within the gastric opening.
43. The system of claim 41, further comprising a fluid for inflating at least one of the first occluding member and the second member.
44. The system of claim 41, further comprising a visible dye or marker infused within at least one of the first occluding member and the second member.
45. The system of claim 41, wherein at least one of the first occluding member and the second member is comprised of a distensible material.
46. The system of claim 41, wherein at least one of the first occluding member and the second member is comprised of a material visually distinct from bodily tissue.
47. The system of claim 41, further comprising a biodegradable covering over each of the first occluding member and the second member, each covering being adapted to degrade upon insertion within a gastric lumen.
48. The system of claim 41, wherein at least one of the first occluding member and the second member is comprised of an expandable foam.
49. The system of claim 41, wherein at least one of the first occluding member and the second member is comprised of an expandable hydrogel.
50. The system of claim 41, wherein at least one of the first occluding member and the second member is comprised of an expandable scaffolding.
51. The system of claim 41, wherein the second member is further adapted to collapse.
52. The system of claim 41, wherein the first occluding member and the second member are in fluid communication through the bridging member.
53. The system of claim 41, wherein the bridging member has a diameter which is less than a diameter of the first occluding member in the inflated state.
54. The system of claim 41, wherein the bridging member is adapted to expand from a first diameter to a larger second diameter.
55. The system of claim 41, wherein the length of the bridging member is tapered.
56. The system of claim 41, wherein the bridging member defines a lumen therethrough.
57. The system of claim 56, further comprising a valve positioned within the lumen.
58. The system of claim 57, wherein the valve comprises a unidirectional valve.
59. The system of claim 57, wherein the valve comprises a passively-controlled valve.
60. The system of claim 57, wherein the valve comprises an actively-controlled valve.
61. The system of claim 41, further comprising at least one inflation port defined upon at least one of the first occluding member and the second member.
62. The system of claim 61, wherein the inflation port is self-sealing.
63. The system of claim 61, wherein the inflation port is comprised of a metallic material.
64. The system of claim 63, wherein the metallic material is magnetic.
65. The system of claim 41, wherein at least one of the occluding members defines a cross-sectional shape along a longitudinal axis, the shape being selected from the group consisting of circles, ellipses, triangles, diamonds, rectangles, squares, and combinations thereof.
66. The system of claim 41, further comprising a first flexible tubing adapted to deliver the first occluding member to the gastric opening.
67. The system of claim 66, wherein the flexible tubing defines a lumen therethrough in fluid communication with at least one of the first occluding member and the second member.
68. The system of claim 66, wherein the flexible tubing further comprises a metallic attachment at a distal end of the tubing.
69. The system of claim 68, wherein the metallic attachment is magnetic.
70. The system of claim 66, further comprising a second flexible tubing adjacent to the first flexible tubing, the second tubing defining a lumen for delivery of fluids therethrough.
71. The system of claim 66, further comprising a third flexible tubing adjacent to the first flexible tubing, the third tubing defining a lumen for aspiration of fluids therethrough.
72. The system of claim 41, further comprising at least one filler defining an occupying volume for occupying a space within a gastric lumen occluded by the first occluding member.
73. The system of claim 72, further comprising a plurality of additional fillers.
Description
RELATED APPLICATION

The present application is a continuation of patent application Ser. No. 10/915,716, filed on Aug. 9, 2004, which is a continuation-in-part of patent application Ser. No. 10/833,950, filed on Apr. 27, 2004, which claims priority to patent application Ser. No. 10/671,191, filed on Sep. 24, 2003, now U.S. Pat. No. 6,994,095, which claims priority to Provisional Patent Application Ser. No. 60/490,421, filed on Jul. 28, 2003, the full disclosures of which are hereby incorporated by reference.

FIELD OF THE INVENTION

The present invention generally relates to weight loss devices. More specifically, the present invention relates to devices for partially and/or intermittently obstructing or reducing the flow of gastric contents across the pyloric valve.

BACKGROUND OF THE INVENTION

Obesity is a condition that has reached epidemic proportions in the United States. Recent government studies have indicated that up to 40% of Americans are obese and that, among those, almost 20% are morbidly obese. Besides personal discomfort and loss of self-esteem, obesity has been associated with multiple pathological conditions, including cardiovascular disease, diabetes, and obstructive sleep apnea.

Many attempts have been disclosed in the prior art to treat obesity, all of which either have shown serious side effects or have proven substantially ineffective. For example, various diets, supplements and pharmaceuticals have been developed and marketed in an attempt to treat obesity, but none of these have provided any significant benefits to date with the exception of some pharmaceutical compositions that have also been associated with a number of serious, life-threatening conditions. To date, there are no commercially available supplements or drugs on the market that have been found to successfully achieve weight reduction.

Recognizing this situation, the medical industry has developed more extreme measures, the best example of which is the Roux-En-Y gastric bypass. More effective, but also potentially lethal, with a 1-2% mortality rate, six month recovery period and a price tag of tens of thousands of dollars, this major surgery is becoming increasingly popular due to the inefficacy of other treatments. Another example is gastric reduction, which basically consists in removing a large segment of the stomach, and which is similar to gastric bypass in its potentially lethal complications.

There is evidence that benefits can be derived from the reduction in gastro-duodenal flow. For instance, a presentation at the American Society for Bariatric Surgery conference in June 2003 indicated that a stimulation of the gastric vagus nerve with subsequent reduction in gastric motility resulted in loss of over 20% of excess weight over a nine month period. There is also data suggesting that a gastric vagotomy is effective in the treatment of obesity trough a similar mechanism. Unfortunately, these therapies require highly invasive surgical procedures that are sometimes irreversible.

SUMMARY OF THE INVENTION

The current invention relates to devices that provide for the treatment of obesity and of related conditions in a safe, controlled, completely non-invasive, and completely reversible manner.

The devices of the present invention generally comprise an occluding member adapted to expand from a first configuration to a larger second configuration, and a bridging member extending from the occluding member. The bridging member has a length that is adapted to pass at least partially through the gastric opening, so to enable the occluding member to obstruct the gastric opening, and that is also adapted to permit the occluding member to intermittently move relative to the gastric opening.

More particularly, a system incorporating the devices described herein may comprise a first occluding member and a second occluding member each adapted to expand from a first configuration to a larger second configuration, with a bridging member extending between the first and the second occluding members. The bridging member has a length that is adapted to pass through the gastric opening, so that the first occluding member obstructs the gastric opening while being retained by the second occluding member, and that is also adapted to permit the first occluding member to move intermittently relative to the gastric opening.

A device according to the present invention may be configured to decrease the flow of contents from the gastric space, e.g., the stomach, into the intestinal tract. This may be accomplished through the placement of a transpyloric device, which is easily placed and removed and which, once placed, may partially and/or intermittently obstruct the pylorus, thereby decreasing the flow of gastric contents into the duodenum.

The reduction in flow through the pylorus can be tightly regulated with an active device, e.g., a pump or metering valve, which, in the case of a pump, may be designed to pump the contents of the stomach into the intestine or, in the case of a metering valve, may be designed to actively control the flow therethrough. Either the pump and/or the metering valve can be operated and powered externally. This active valve or pump variation may also incorporate temperature, pressure, or pH sensors in order to determine when the active valve or pump should be engaged. Moreover, this reduction in flow can be more loosely regulated through the use of a passive flow reduction mechanism, which span the pyloric valve and decrease the effective diameter of the pyloric valve. Furthermore, both the active and passive embodiments can be adapted to incorporate slow-release drug delivery and electrical stimulation technologies.

Applications of the present invention include weight reduction and treatment of malabsorption syndromes, among others. In addition to the reduction of gastro-duodenal transit, the active mechanisms can be used to increase food transit, thereby causing the dumping characteristic of an effective gastric bypass surgery. Both of the variations can also incorporate an expansible foam in the inflatable portion, in order to prevent accidental rupture of the device with subsequent intestinal migration. With the presence of foam, any potential puncture of the inflatable membrane (ideally made of silicone or other biocompatible material) would result in maintenance of volume of the present invention.

The devices of the present invention can be placed either using endoscopy with direct placement, or through simple ingestion with programmed inflation of the occlusion members to effect the pyloric anchoring. For example, one of the occlusion members could have its inflation port covered by an acid-sensitive coating while the other is acid-resistant but erodes at the pH found in the intestine (about 6.0). Thus, once the device is ingested, one of the occlusion members will expand retaining the device in the gastric space, after which gastric motility will eventually move the remaining uninflated occlusion member into the intestine. Once the second occlusion member contacts the intestinal tract, the inflation port may be eroded by the intestinal milieu and the second portion may slowly inflate leaving the device spanning the pyloric valve.

During removal, the device may be equipped with a metallic ring around its inflation port in the gastric space. Once removal is desired, a magnet-tipped suction catheter may be advanced into the patient (or placed using a nasogastric tube). Once an optional sensor has indicated that the magnet has engaged the metallic ring, a vacuum may be activated and the entire device deflated through rupture of a pressure-sensitive barrier in the case of the dual inflation mechanism, or through simple application of vacuum forces. In the dual inflation port variation, while the intestinal port may remain open, the inflation port may be designed for low-flow such that a vacuum force will overwhelm its intake capabilities and allow for the decompression of the entire device. In the instance that the device has been ruptured or punctured and suction is not able to compress the expansible foam, the device may be removed using endoscopy.

In alternative variations, the device can be composed of a slowly degrading polymer placed either through endoscopy or through ingestion. In yet another variation, the device can be placed by endoscopy and be formed from semi-rigid compounds to ensure its integrity in the hostile gastric environment. The inflatable portion of the device could take virtually any shape provided that it intermittently occludes the pyloric valve and does not cause permanent occlusion.

The bridging member between the inflatable portions can be a variety of sizes including a millimeter or less, in order to not significantly reduce pyloric sphincter diameter, up to 8-10 mm, in order to severely reduce the functional diameter of the pyloric sphincter and achieve obstruction of flow in this manner as well.

The devices may also be utilized with a number of gastric fillers and may be used to prevent premature passage of the gastric filler as well as to maintain a sensation of fullness for the patient. To this end, the bridging member or tether between the two occlusion members can be of varying diameter ranging from less than 1 mm up to 10 mm in diameter to provide reduction of the functional diameter of the pyloric sphincter and/or to prevent premature intestinal migration of a gastric filler. The gastric filler used with this device may be as simple as a dietary fiber to as complex as a specifically designed polymer. Regardless of the filler used, the devices may assist in gastric retention of the filler.

The devices described herein may incorporate a number of safety features. For instance, the devices may incorporate an expansible foam inside the expanding portions of the device, which may ensure that any minimal (or even extensive) puncture will not result in distal migration of the device with potential small bowel obstruction. Instead, the device will remain in place straddling the pylorus leaving the remainder of the bowel undisturbed. The external surface of the device may be made of a variety of biocompatible materials, e.g., silicone, although any biocompatible, airtight surface will work also.

Another safeguard may include the use of bright coloring in the expansible foam, e.g., visually distinct dyes or markers. Thus, with instructions to examine a patient's feces (at least cursorily), a patient or a physician will receive an indication that there may be compromise of the device, however unlikely, when there are brightly colored flecks in the patient's feces. Alternatively, the device may be designed to compress with rupture. In this variation, the device may not include any expansible foam, but instead have an inherent elasticity, which provides for complete collapse of the device with rupture. This collapsibility could be provided by elastic members inside the inflatable members or use of an elastic material for the device itself. This safeguard may not prevent intestinal passage, but may instead encourage complete passage through the entire bowel in the instance of rupture.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A to 1C show cross-sectional views of one variation of a pyloric corking device designed to partially and/or intermittently obstruct a gastric opening in an unexpanded, partially unexpanded, and fully expanded configuration, respectively.

FIGS. 2A to 2D show side views of variations of the device utilizing occlusion members of different shapes.

FIGS. 3A to 3C show cross-sectional views of another variation of the pyloric corking device.

FIG. 4A shows a side view of yet another variation of the device having a tapered bridging member.

FIG. 4B shows a side view of yet another variation of the device having conical occlusion members held at a distance from one another.

FIGS. 5A and 5B show side views of yet another variation of the device having a single occlusion member and alternative anchor members.

FIGS. 6A to 6C show cross-sectional views of the stomach and one variation for nasogastric (or endoscopic) placement of a non-ingestible variation of the device.

FIGS. 7A to 7C show cross-sectional views of the stomach and another variation for nasogastric (or endoscopic) placement of a non-ingestible variation of the device.

FIGS. 8A to 8D show cross-sectional views of the stomach and yet another variation for placement of a variation of the device through ingestion.

FIGS. 9A to 9D show cross-sectional views of the stomach and yet another variation for placement of another variation of the device through ingestion.

FIGS. 10A to 10D show cross-sectional views of the stomach and one variation for removal of the device.

FIGS. 11A and 11B show top and perspective views, respectively, of an alternative variation of the device incorporating multiple prongs designed to intermittently obstruct the pyloric valve.

FIGS. 12A and 12B show side and top views, respectively, of another variation of the device incorporating multiple prongs designed to intermittently obstruct the pyloric valve.

FIGS. 13A to 13D show cross-sectional views of an alternative use of the device for preventing gastro-duodenal reflux during tube feeding.

FIGS. 14A to 14D show cross-sectional views of an alternative use of the device in combination with one or several gastric fillers.

DETAILED DESCRIPTION OF THE INVENTION

FIGS. 1A to 1C are cross-sectional views showing the expansion, respectively, of one variation of a pyloric corking device, which is designed to partially and/or intermittently obstruct a gastric opening, particularly the pyloric valve. In this particular variation, FIG. 1A illustrates the device 4 in an unexpanded or uninflated state and ready for delivery and/or insertion into the pyloric valve. FIG. 1B shows the distal occlusion member 14 in an expanded state. In use, once the device 4 has been placed, e.g., in the pyloric region or beyond, the distal occlusion member 14 may be inflated through the influx of any number of biocompatible fluids or gases, e.g., saline, water, air, nitrogen, etc., through the tubing 8 leading to the inflation port 6, which may be self-sealing. Tubing 8 may include any number of delivery tubes such as catheters, endoscopes, etc.

The distal occlusion member 14 may be configured to inflate before the inflation of proximal occlusion member 16 by fabricating the inflatable member of distal occlusion member 14 with a material, which is more easily distensible relative to a material of the proximal occlusion member 16. Materials which may be used in fabricating the occlusion members 14, 16 may include any number of materials such as silicone, silicone elastomers, latex, polyurethane, PTFE, FEP, etc. Alternatively, self-expanding materials, such as foam or hydrogels, which typically expand upon contact with fluids, may be utilized within the occlusion members 14, 16. If such self-expanding materials are utilized, they may be disposed in the occlusion member 14, 16 and a fluid such as saline, may be infused to expand the materials. Different self-expanding materials may be incorporated in the distal occlusion member 14 than in the proximal occlusion member 16 to obtain differing radial pressures exerted by the expanding materials.

In yet another alternative, an expanding scaffolding may be utilized within each of the occlusion members 14, 16. Such a scaffold may be made of a shape memory alloy or super-elastic alloy, such as Nitinol. The scaffold may be compressed into a delivery configuration and then either allowed to expand into the desired occlusive shape by self-expansion or by supplying an activation energy, e.g., electrical, heat, RF energy, etc. In either case, the distal occlusive member 14 may be positioned distal of the pyloric valve and then inflated or expanded into its larger configuration. It may then be pulled proximally against the pyloric annulus, at which point proximal occlusive member 16 may be inflated or expanded by infusion through port 6, as shown in FIG. 1C. With both occlusion members 14, 16 inflated or expanded, bridging member 10 connecting the two may span the pylorus. Bridging member 10 may be of various diameters, e.g., 1 mm and less (in order to not significantly reduce pyloric sphincter diameter) or up to 8 10 mm in diameter (to severely reduce the functional diameter of the pyloric sphincter and achieve obstruction of flow in this manner as well).

Bridging member 10 may be designed to have a flexible length sufficient to allow the occlusion members 14, 16 to maintain its position with respect to the pyloric valve yet still enable the members 14, 16 to move. Proximal occlusion member 16 may move from fully obstructing the pyloric valve to moving proximally of the pyloric valve to the extent that distal occlusion member 14 allows member 16 to move. This movement may be elicited by the natural movements of the gastric lumen (stomach) and muscles surrounding the pyloric valve. Thus, when proximal occlusion member 16 is moved proximally, the pyloric valve is only partially obstructed and may allow for the intermittent passage of food-between the bridging member 10 and the valve. Because any food within the stomach is retained for longer periods of time, feelings of satiation may be initiated sooner and prolonged so that the patient consumes less food. Moreover, to allow for the relative movement of the occlusion members 14, 16, bridging member 10 may be of a length, which is sufficient to allow for its placement through the pyloric valve (or through another gastric opening) such that there is sufficient tolerance for the occlusion members 14, 16 to move proximally and distally relative to the pyloric valve. For instance, in the event that a patient's pyloric valve extends about 2 cm in length, the bridging member 10 is preferably longer than 2 cm, for example, up to 5 cm in length. Moreover, while occlusion members 14, 16 are inflatable or expandable, bridging member 10 itself may be configured to inflate or expand in diameter.

A visible dye or marker, preferably being highly visible, may optionally be infused into one or both of the occlusion members 14, 16 to function as a safety measure. Alternatively, one or both of the occlusion members 14, 16 may optionally be fabricated from a material which is highly visible and visually distinct from bodily tissue so that in the unlikely event of an occlusion member 14, 16 rupturing, the dye or pieces of the occlusion member 14, 16 may become visible once passed from the body. This may indicate to the patient or physician that a rupture of the device has occurred.

Another variation may incorporate slow-releasing drugs infused into the materials covering the device or materials incorporated into the device. These drugs, which may be any number of drugs, may slowly infuse into the patient by drug release into the intestinal tract or through contact with the patient. Alternatively, the devices may incorporate electrical stimulation technologies. For instance, electrical probes may extend from a surface of the device for insertion into the surrounding tissue or electrodes may be formed over a surface of the device instead.

In yet another alternative, the occlusion members 14, 16 may be covered by an erodable or biodegradable covering over one or both members 14, 16. Such a covering may be configured to constrain one or both members 14, 16 and once the device has been ingested or placed within the gastric lumen, contact with the surrounding fluids may naturally erode the covering thus allowing the covered occlusion member to expand or inflate. In another variation, proximal and distal occlusion members may each be covered by different materials each configured to erode at differing rates or in different environments, as described in further detail below.

In the variation shown in FIGS. 1A to 1C, the device 4 may include an optional lumen 18 defined through the device 4. Optional lumen 18 may allow for the passage of fluids and food through the device 4 entering the lumen 18 through entry port 2 and exiting through the exit port 20. The lumen 18 may be designed to allow for the passage of a reduced volume of food through the device 4, in which case the device 4 shown may be configured with a relatively shortened bridging member 10 to inhibit the relative movement of the device 4 relative to the pylorus. With this variation, the lumen 18 has been configured so that it may be capable of actively pumping or metering the contents of the gastric lumen 74 into the intestine 76 through the device 4. In such a case, the need for the device 4 to be able to move to un-occlude the pyloric valve is removed. As shown in the figures, an optional pump or active metering valve 12 may be incorporated into the device 4. Pump or valve 12 may be configured to simply open and allow for the passage of the stomach contents through lumen 18 and valve 12 upon sensing the presence of foreign objects, such as food, in the stomach or upon sensing a predetermined pressure from the contents. Other sensing parameters may include temperature and pH levels. Alternatively, the pump or valve 12 may be configured to actively pump the stomach contents through the lumen 18 via a pumping mechanism automatically activated by pump or valve 12 or externally activated by the patient or physician through wireless communication. In the case where the device is configured with a valve 12, the valve may be configured as a unidirectional valve to allow the flow of fluids and food only from the stomach to the intestinal tract.

The device 4 could have any shape provided that the shape and/or total volume of the proximal occlusion member 16 is sufficient to prevent its passage through the pyloric valve and into the intestines. FIGS. 2A to 2D show side views of different shape variations, which are possible for use as occlusion members. For instance, FIG. 2A shows a side view of a device variation 22 in which proximal and distal occlusion members 24, 26 have a cross-sectional shape along a longitudinal axis defined by the device 22 in the form of circles, to form spherical occlusion members. Although proximal and distal occlusion members 24, 26 are illustrated having equally sized diameters, the diameters may be varied depending upon the desired shape and device configuration. For instance, proximal occlusion member 24 may be configured to have a diameter larger than distal occlusion member 26. Alternatively, a device having the opposite configuration may also be utilized, although this may be less preferable. Lumen 28 and pump or valve 12 may be optionally included, again depending upon the desired device configuration.

FIG. 2B shows another device variation in which proximal and distal occlusion members 30, 32 may have a cross-sectional shape along a longitudinal axis defined by the device in the form of ellipses, to form ellipsoids. The major axes of the elliptically-shaped occlusion members 30, 32 are preferably oriented perpendicularly relative to the longitudinal axis of the device in this variation, although various angles may be formed as well. FIG. 2C shows the variation in which proximal and distal occlusion members 34, 36 may be formed as triangles, to form conically-shaped occlusion members. In this variation, bridging member 38 may be minimal in length and may simply be formed by the intersection of the occlusion members 34, 38 to form a waist region. FIG. 2D shows yet another variation in which proximal and distal occlusion members 40, 42 may be formed as diamond shapes, to form a variation of conically-shaped occlusion members. This variation may also form a waist region 44.

Although these variations show specific shapes, these are merely intended to be illustrative of the various types of shapes, which may be utilized and is not intended to be limiting. For instance, any shape, such as rectangles, squares, etc., which may function to occlude a gastric opening and prevent the device from falling therethrough may be utilized and are within the scope of this disclosure. Moreover, various combinations of the different shapes as occlusion members on a single device may also be utilized, such as a device having a distal occlusion member in the shape of a sphere and a proximal occlusion member in the shape of a cone.

FIGS. 3A to 3C show cross-sectional views of another variation of a pyloric corking device, which is also designed to intermittently obstruct a gastric opening. Similar to the device shown in FIGS. 1A to 1C, this particular variation omits the use of a lumen defined through the entire device 46. This device 46 may also incorporate any of the features described above for expanding the occlusion members. For instance, foam of varying expansion pressures may be utilized to ensure that expansion occurs in the distal occlusion member 50 prior to expansion in the proximal occlusion member 48 upon the injection of a fluid, e.g., saline or water, into the device 46. The device 46 has been designed though, so that the influx of fluids from the infusion tubing 8 through the entry port 6 is channeled through the lumen 52 of the central portion from the proximal occlusion member 48 to the distal occlusion member 50. The device 46 may also be placed in the same manner as the device of FIGS. 1A to 1C, as described in further detail below. This variation may also incorporate an inflation port 6, which may be metallic, so that removal of the device 46, if necessary, can be accomplished through the simple placement of a magnetically tipped suction catheter. The catheter, when appropriately placed, may cause the device to deflate by applying a suction force to facilitate the easy removal of the device 46 from the pyloric valve. The device 46 can thus be removed through any endoscopic or percutaneous approach, e.g., an oro- or naso-gastric approach. While this variation may have a lumen 52 connecting the proximal 48 and distal 50 occlusion members, this lumen 52 may be closed to gastric space and instead be used to communicate an inflation fluid to inflate the occlusion members 48, 50. The occlusion members of the device 46 may have any shape as described above, for instance in FIGS. 1A to 2D.

Yet another variation of the device is shown in FIG. 4A. In this variation the device 54 may have a bridging member 60 that is tapered. The bridging member 60 may be tapered to become wider along its length from the distal occlusion member 58 to the proximal occlusion member 56. The tapered bridging member 60 may be utilized to facilitate movement of the device 54 to un-occlude the pyloric valve. As the pyloric valve contracts about the bridging member 60, the taper may aid in moving the device proximally. The angle of the taper may be varied, depending upon the desired results, as may the size and shapes of the occluding members 56, 58.

FIG. 4B shows yet another variation similar to that shown above. In this variation, the device 55 may have occlusion members 57, 59 having conically-shaped members which are connected via a bridging member 61. This bridging member 61 may have a length, which holds occlusion members 57, 59 at a distance from one another sufficient to enable the device 55 to move relative to the pyloric valve. The device 55 may inflate or expand the occlusion members 57, 59 using any of the methods disclosed herein and the device 55 may also optionally incorporate a central lumen and a passive or active valve or pumping mechanism, if desired.

In yet another variation, the distal occlusion member may be omitted entirely.

FIG. 5A, for instance, shows a side view of an alternative variation 62 in which the bridging member 66 may extend at some length, e.g., 5 cm or greater, from a proximal occlusion member 64. The bridging member 66 may be placed within the intestinal tract, e.g., the duodenum, while held in place by the proximal occlusion member 64 abutting the pyloric valve. The positioning of the proximal occlusion member 64 relative to the pyloric valve may be maintained by the frictional forces generated by the bridging member 66 rubbing against the walls the intestinal tract. The occlusion member 64 may function in the same manner as described above in intermittently un-occluding the pyloric valve during stomach contractions and movement, but may be held in place by the length of the bridging member 66. Although the distal end of the bridging member 68 may be free-floating in the intestinal tract, it may optionally be weighted by a weight 68 or by a number of hooks or barbs 72 for attachment to the intestinal walls, as shown in the device 70 of FIG. 5B.

It is furthermore within the scope of this disclosure that certain features between the different device variations described herein may be incorporated into various combinations. For instance, a device having a proximal occlusion member having a spherical shape and a distal occlusion member having a conical shape may be utilized. As a further example, this device may also incorporate various methods to inflate or expand the distal occlusion member in a different manner as the proximal occlusion member. Moreover, this device may also have a biodegradable covering over only one occlusion member and may also incorporate the valve and/or pump integrated within the device and may also optionally include a lumen defined throughout the length of the device. These examples are merely intended to be illustrative of the various combinations which may be employed by combining various aspects from different variations described herein and are intended to be within the scope of this invention.

FIGS. 6A to 6C show cross-sectional views of the stomach and one variation for nasogastric (or endoscopic) placement of a non-ingestible, active variation of the device 4. As the device 4 is delivered through the esophagus 78, it may be in a compressed, un-inflated, or un-expanded configuration, as shown in FIG. 6A, while being positioned via the optional tubing 8. Once the device 4 has been positioned to span the pylorus with the occlusion members in the stomach 74 and duodenum 76, respectively, the device 4 may be inflated or expanded using any of the methods described above, as shown in FIG. 6B. The tubing 8 may then be detached and the device 4 left in place, as shown in FIG. 6C.

FIGS. 7A to 7C show cross-sectional views of the stomach and another variation for nasogastric (or endoscopic) placement of a non-ingestible, passive variation of the device 46. As above, the device 46 may be advanced through the esophagus 78 while in a compressed, un-inflated, or un-expanded configuration, as shown in FIG. 7A. As shown in FIG. 7B, once the device 46 has been placed spanning the pylorus with the occlusion members in the stomach 74 and duodenum 76, respectively, the device may be inflated or expanded and the tubing 8 may be detached and the device 46 left in place, as shown in FIG. 7C.

FIGS. 8A to 8D show cross-sectional views of the stomach and yet another variation for placement of a passive embodiment of the device 80. As shown in FIG. 8A, the device 80 may be simply ingested. As it enters the stomach 74, gastric fluids may erode an acid sensitive coating over the inflation port of the proximal occlusion member 82. Once the coating has degraded, the proximal occlusion member 82 may be configured to expand or inflate, as shown in FIG. 8B. Once the expansion or inflation has occurred, the device 80 will remain in the stomach 74 and eventually the distal occlusion member 84 may pass into the duodenum 76 while still in its un-expanded or un-inflated state due to the natural contractions of the stomach, as shown in FIG. 8C. Once the distal occlusion member 84 has passed into the duodenum 76, an alkaline sensitive coating over the distal occlusion member 84 may be eroded and expansion or inflation of the distal occlusion member 84 will occur with the device spanning the pyloric valve, as shown in FIG. 8D. The covering over the distal occlusion member 84 may be configured to erode only once it has contacted the acidic environment specific to the duodenum 76, where the pH level is approximately 6. In order to facilitate removal, the two occlusion members 82, 84 may be connected by a central, hollow lumen 86, as described above, with a barrier 88 designed to rupture upon the application of a predetermined pressure level. Thus, with application of a vacuum having the appropriate pressure level, the barrier 88 may be configured to rupture and the entire device 80 may be deflated.

FIGS. 9A to 9D show cross-sectional views of the stomach and yet another variation for placement of a passive variation of the device 90 through ingestion. In this alternative variation, the device 90 can be ingested orally. As the device 90 enters the stomach 74, shown in FIG. 9A, both the proximal and distal occlusion members 82, 92, respectively, may be configured to inflate upon erosion of acid-sensitive coatings over the inflation port or device 90, as shown in FIGS. 9B and 9C. Once inflation or expansion has been accomplished, the distal occlusion member 92 will eventually be passed due to its smaller size (approximately the diameter of the dilated pyloric valve 5 15 mm) while the proximal occlusion member 82 will remain in the stomach 74 due to its larger size, e.g., 15 mm or greater in diameter and up to 60 mm in diameter due to physiologic limitations in the pyloric region of the stomach, as shown in FIG. 9D. Thus, one occlusion member 92 may be designed to be small enough to be passed through the pyloric valve while the proximal occlusion member 82 may be designed to be retained in the stomach 74 with both occlusion members 82, 92 inflating in the stomach 74.

FIGS. 10A to 10D show cross-sectional views of the stomach 74 showing one variation for removal of the device 80 (passive variation illustrated). The device 80 is shown in FIG. 10A between the stomach 74 and the duodenum 76. As seen in FIG. 10B, a magnetic tipped suction catheter or endoscope 94 is introduced and the device 80 may be deflated and removed, as shown in FIGS. 10C and 10D. In contacting the inflation port 6 with the catheter 94, the tip may be configured with an electrical contact as an aid in determining whether the catheter 94 has properly contacted the inflation port 6. Alternatively, the device 80 may be removed through endoscopy or it may be designed to degrade over time and eventually be passed through the intestines.

FIGS. 11A and 11B show top and perspective views, respectively, of an alternative variation for the device, which may reside solely in the stomach. This particular variation may incorporate multiple prongs 100, 102, 104, 106, 108, 110 designed to intermittently cork the pylorus. In this variation, an expansible material 96 may be appropriately shaped in order to promote occlusion of the pylorus. The device may be ejected from the pylorus due to contractions, but may be re-inserted through one of the various prongs. As a further measure, the device may define multiple apertures 98 through each set of prongs to prevent complete obstruction of the pyloric valve.

FIGS. 12A and 12B show side and top views, respectively, of another variation of the device of FIGS. 11A and 11B. In this variation, a fewer number of multiple prongs 112, 114, 116, 118 may be utilized and each prong may also define an aperture 120 therethrough. However, as shown in this variation, each of the prongs may be flexible and tapered or rounded to prevent damage to the surrounding tissue.

FIGS. 13A to 13D show cross-sectional views of an alternative use of the devices described herein. In this variation, the device may be utilized in the prevention of gastro-duodenal reflux during tube feeding. As shown, the device 124 is similar to variations described above; however, in this variation, a lumen 132 defined through the device 124 for tube feed delivery may define an outlet 134 designed to be positioned in the duodenum 76. The proximal portion of the device 124 may also be attached to a feeding tube 126 and an inflation tubing 130. Feeding tube 126 may be used to deliver tube feeds through the lumen 132 directly to the duodenum 140 while the inflation tubing 130 may be used to inflate an inflatable pyloric spanner or bridging member 136 during tube feeding to prevent reflux of delivered material 140. The device 124 can also incorporate a third tube 128 which may provide for aspiration of the gastric contents 138 to prevent reflux of the delivered material into the lungs and to decompress the stomach 74. The proximal portion of the occlusive member can either maintain its inflated or expanded state or it can be decompressed at times to relieve pressure on the pyloric valve. In this variation, a percutaneous approach is shown, but a nasogastric approach or another approach is possible.

FIGS. 14A to 14D show cross-sectional views of yet another alternative use with devices of the present invention. As shown in FIGS. 14A to 14C, a device 90 may be placed to occlude the pyloric valve. In this case, the device 90 is shown as having been ingested, although placement of the device 90 may be effected via any of the methods described above. As shown in FIG. 14D, the addition of one or several gastric fillers 142, e.g., inflatable gastric balloons, expandable scaffolding, or any other number of space-occupying devices generally known in the art, may be utilized. In this variation, the device 90 may be placed and then the gastric fillers 142 may be introduced. The device 90 may be utilized to ensure that the gastric fillers 142 are not passed through the pyloric valve until they are sufficiently small, thereby allowing for non-degradable substances to be utilized without the concomitant risk of small bowel obstruction.

The applications of the inventive devices discussed above are not limited to certain treatments, but may include any number of maladies. Modification of the above-described methods and devices for carrying out the invention, and variations of aspects of the invention that are obvious to those of skill in the art are intended to be within the scope of the claims. Moreover, various combinations of aspects between examples are also contemplated and are considered to be within the scope of this disclosure.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US249904516 Aug 194828 Feb 1950Herman Young FrankRectal dilator and medicator
US31540774 Jun 196227 Oct 1964Joseph P CannonHemostatic device for anal surgery
US39151716 Jun 197428 Oct 1975Dennis William ShermetaGastrostomy tube
US413331527 Dec 19769 Jan 1979Berman Edward JMethod and apparatus for reducing obesity
US424041229 Aug 197923 Dec 1980Eugene JamesMedical device
US42468935 Jul 197827 Jan 1981Daniel BersonInflatable gastric device for treating obesity
US43111468 May 198019 Jan 1982Sorenson Research Co., Inc.Detachable balloon catheter apparatus and method
US431550916 Oct 197816 Feb 1982Smit Julie AInsertion and removal catheters and intestinal tubes for restricting absorption
US43412186 Mar 198027 Jul 1982University Of CaliforniaDetachable balloon catheter
US436873929 Apr 198118 Jan 1983Nelson Jr Richard LLong intestinal catheter
US441626710 Dec 198122 Nov 1983Garren Lloyd RMethod and apparatus for treating obesity
US448580524 Aug 19824 Dec 1984Gunther Pacific Limited Of Hong KongWeight loss device and method
US451797914 Jul 198321 May 1985Cordis CorporationDetachable balloon catheter
US459869910 Jun 19858 Jul 1986Garren Lloyd REndoscopic instrument for removing stomach insert
US464838322 Jul 198510 Mar 1987Angelchik Jean PPeroral apparatus for morbid obesity treatment
US465702010 Jul 198514 Apr 1987Jayco PharmaceuticalsMethod of using a foreign object protector hood
US469482714 Jan 198622 Sep 1987Weiner Brian CInflatable gastric device for treating obesity and method of using the same
US47352145 Sep 19865 Apr 1988Berman Irwin RGastrointestinal diagnostic capsule and method of use
US47621289 Dec 19869 Aug 1988Advanced Surgical Intervention, Inc.Method and apparatus for treating hypertrophy of the prostate gland
US48362046 Jul 19876 Jun 1989Landymore Roderick WMethod for effecting closure of a perforation in the septum of the heart
US487890510 Aug 19887 Nov 1989Blass Karl GGastrointestinal module: a nonsurgical implant
US49254466 Jul 198815 May 1990Transpharm Group Inc.Removable inflatable intragastrointestinal device for delivering beneficial agents
US493049622 Jul 19885 Jun 1990Vance Products, Inc.Method and device for removing a stone from a ureter using extracorporeal shock wave lithotripsy
US49464405 Oct 19887 Aug 1990Hall John EEvertible membrane catheter and method of use
US501148820 Aug 199030 Apr 1991Robert GinsburgThrombus extraction system
US51084201 Feb 199128 Apr 1992Temple UniversityAperture occlusion device
US512991531 May 198914 Jul 1992Jose CantenysIntragastric balloon
US51923013 Sep 19919 Mar 1993Nippon Zeon Co., Ltd.Closing plug of a defect for medical use and a closing plug device utilizing it
US524644524 Jan 199221 Sep 1993Instent Inc.Device for the treatment of constricted ducts in human bodies
US5282829 *15 Aug 19911 Feb 1994United States Surgical CorporationHollow body implants
US530630022 Sep 199226 Apr 1994Berry H LeeTubular digestive screen
US531234323 Nov 199017 May 1994Michael KrogDevice for segmental perfusion and aspiration of colon and rectum
US542387226 May 199313 Jun 1995Cigaina; ValerioProcess and device for treating obesity and syndromes related to motor disorders of the stomach of a patient
US550988826 Jul 199423 Apr 1996Conceptek CorporationController valve device and method
US551409125 May 19947 May 1996Yoon; InbaeExpandable multifunctional manipulating instruments for various medical procedures
US551417827 May 19947 May 1996SynthelaboProsthesis for bodily canal
US554070120 May 199430 Jul 1996Hugh SharkeyPassive fixation anastomosis method and device
US554521022 Sep 199413 Aug 1996Advanced Coronary Technology, Inc.Method of implanting a permanent shape memory alloy stent
US56349366 Feb 19953 Jun 1997Scimed Life Systems, Inc.Device for closing a septal defect
US5674192 *23 Jul 19937 Oct 1997Boston Scientific CorporationDrug delivery
US56766881 Jul 199614 Oct 1997Rtc, Inc.Variably inflatable medical device
US570735515 Nov 199513 Jan 1998Zimmon Science CorporationApparatus and method for the treatment of esophageal varices and mucosal neoplasms
US57505854 Apr 199512 May 1998Purdue Research FoundationSuper absorbent hydrogel foams
US57529715 Jun 199519 May 1998Boston Scientific Technology, Inc.Method of treating a flow obstruction
US578280017 Dec 199621 Jul 1998Yoon; InbaeExpandable multifunctional manipulating instruments for various medical procedures and methods therefor
US582058428 Aug 199713 Oct 1998Crabb; Jerry A.Duodenal insert and method of use
US585342223 Sep 199729 Dec 1998Scimed Life Systems, Inc.Apparatus and method for closing a septal defect
US59479917 Jan 19977 Sep 1999Cowan; Robert K.Single balloon device for cervix
US5976174 *15 Dec 19972 Nov 1999Ruiz; Carlos E.Medical hole closure device and methods of use
US606799113 Aug 199830 May 2000Forsell; PeterMechanical food intake restriction device
US610292819 Jan 199915 Aug 2000General Surgical Innovations, Inc.Method of dissecting tissue layers
US611270322 Jun 19995 Sep 2000Jw Pet Company, Inc.Shrouded chewable pet toys and method of making
US611715922 Dec 199812 Sep 2000Scimed Life Systems, Inc.Apparatus and method for closing a septal defect
US61521446 Nov 199828 Nov 2000Appriva Medical, Inc.Method and device for left atrial appendage occlusion
US615921916 May 199712 Dec 2000Scimed Life Systems, IncStent retrieval device
US61622011 Jun 199819 Dec 2000Cohen; Kenneth L.Internal urinary catheter
US618352010 Nov 19986 Feb 2001Galt Laboratories, Inc.Method of maintaining urinary continence
US62450909 Nov 199812 Jun 2001Salviac LimitedTranscatheter occluding implant
US6270515 *26 Feb 19977 Aug 2001Scimed Life Systems, Inc.Device for closing a septal defect
US63719742 Aug 199916 Apr 2002Sub Q, Inc.Apparatus and method for percutaneous sealing of blood vessel punctures
US640965613 Oct 199825 Jun 2002Patrick SangouardArtificial sphincter with magnetic control
US645478523 Feb 200124 Sep 2002DE HOYOS GARZA ANDRéSPercutaneous intragastric balloon catheter for the treatment of obesity
US648896220 Jun 20003 Dec 2002Depomed, Inc.Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US65032643 Mar 20007 Jan 2003Bioenterics CorporationEndoscopic device for removing an intragastric balloon
US652770129 Sep 20004 Mar 2003Precision Medical Devices, Inc.Body fluid flow control device
US652773929 Dec 20004 Mar 2003Advanced Cardiovascular Systems, Inc.Spiraled balloon arrangement for treatment of a tortuous vessel
US654078910 Nov 20001 Apr 2003Scimed Life Systems, Inc.Method for treating morbid obesity
US654429126 Mar 20018 Apr 2003Thomas V. TaylorSutureless gastroesophageal anti-reflux valve prosthesis and tool for peroral implantation thereof
US655840030 May 20016 May 2003Satiety, Inc.Obesity treatment tools and methods
US657930117 Nov 200017 Jun 2003Syntheon, LlcIntragastric balloon device adapted to be repeatedly varied in volume without external assistance
US660095311 Dec 200029 Jul 2003Impulse Dynamics N.V.Acute and chronic electrical signal therapy for obesity
US665257811 May 200125 Nov 2003Abps Venture One, Ltd.Endoluminal cardiac and venous valve prostheses and methods of manufacture and delivery thereof
US667580927 Aug 200113 Jan 2004Richard S. StackSatiation devices and methods
US668904628 Sep 200110 Feb 2004Precision Medical Devices, Inc.Body fluid flow control method and device
US670284628 Feb 20029 Mar 2004Endocare, Inc.Urological stent therapy system and method
US674012125 Jan 200225 May 2004Boston Scientific CorporationIntragastric stent for duodenum bypass
US675586925 Jan 200229 Jun 2004Boston Scientific CorporationIntragastric prosthesis for the treatment of morbid obesity
US680286810 Mar 200312 Oct 2004Scimed Life Systems, Inc.Method for treating morbid obesity
US686089518 Jun 19991 Mar 2005Radi Medical Systems AbTool, a sealing device, a system and a method for closing a wound
US699409524 Sep 20037 Feb 2006Medventure Associates IvPyloric valve corking device and method
US70116214 Mar 200314 Mar 2006Precision Medical Devices, Inc.Body fluid flow control method and device
US703734431 Oct 20032 May 2006Valentx, Inc.Apparatus and methods for treatment of morbid obesity
US705469022 Oct 200330 May 2006Intrapace, Inc.Gastrointestinal stimulation device
US708707222 Jan 20038 Aug 2006Cardia, Inc.Articulated center post
US712049823 Oct 200310 Oct 2006Intrapace, Inc.Method and device for securing a functional device to a stomach
US71212834 Mar 200417 Oct 2006Synecor, LlcSatiation devices and methods
US71220582 Dec 200317 Oct 2006Gi Dynamics, Inc.Anti-obesity devices
US714698412 Mar 200312 Dec 2006Synecor, LlcMethod and apparatus for modifying the exit orifice of a satiation pouch
US71603124 Nov 20029 Jan 2007Usgi Medical, Inc.Implantable artificial partition and methods of use
US71677506 Jan 200423 Jan 2007Enteromedics, Inc.Obesity treatment with electrically induced vagal down regulation
US718625125 Feb 20046 Mar 2007Cierra, Inc.Energy based devices and methods for treatment of patent foramen ovale
US729116017 Mar 20036 Nov 2007Delegge RebeccaIntragastric catheter
US7320696 *21 Jun 200422 Jan 2008Bashir Mussa GaziSemi-stationary balloon in the gastric antrum provided with connecting an anchoring rod for inducing weight reduction in human beings
US758858422 Dec 200415 Sep 2009General Surgical Innovations, Inc.Methods and devices for blood vessel harvesting
US784205330 Mar 200530 Nov 2010Nmt Medical, Inc.Double coil occluder
US804816927 Apr 20041 Nov 2011Baronova, Inc.Pyloric valve obstructing devices and methods
US82573894 May 20054 Sep 2012W.L. Gore & Associates, Inc.Catching mechanisms for tubular septal occluder
US2002001360129 Jan 200131 Jan 2002Nobles Anthony A.Cavity enlarger method and apparatus
US2002003810019 Sep 200128 Mar 2002Masayoshi OkadaIntra-arterial shunt tube and method of using same
US200200913958 Jan 200111 Jul 2002Shlomo GabbaySystem to inhibit and/or control expansion of anatomical features
US20020161341 *26 Apr 200131 Oct 2002Stinson Jonathan S.Gastric pseudocyst drainage and stent delivery system for use therein
US200201655891 May 20017 Nov 2002Imran Mir A.Gastric treatment and diagnosis device and method
US2002018835412 Jun 200112 Dec 2002Peghini Paolo LinoDevice to treat obesity by obstructing gastric outlet
US2002019847026 Jun 200126 Dec 2002Imran Mir A.Capsule and method for treating or diagnosing the intestinal tract
US2003002315025 Jul 200230 Jan 2003Olympus Optical Co., Ltd.Capsule-type medical device and medical system
US2003004080427 Aug 200127 Feb 2003Stack Richard S.Satiation devices and methods
US2003007861117 May 200224 Apr 2003Kiyoshi HashibaIntragastric device for treating obesity
US200300931174 Nov 200215 May 2003Vahid SaadatImplantable artificial partition and methods of use
US2003010993125 Jan 200212 Jun 2003Boston Scientific CorporationIntragastric stent for duodenum bypass
US2003010993525 Jan 200212 Jun 2003Boston Scientific CorporationIntragastric prosthesis for the treatment of morbid obesity
US2003012032821 Dec 200126 Jun 2003Transneuronix, Inc.Medical implant device for electrostimulation using discrete micro-electrodes
US2003014470817 May 200231 Jul 2003Starkebaum Warren L.Methods and apparatus for retarding stomach emptying for treatment of eating disorders
US2003015260113 Jun 200114 Aug 2003Masanori KanayamaOily cosmetics
US2003015380620 Feb 200314 Aug 2003Ev&MActive tissue augmentation materials and method
US2003015860110 Mar 200321 Aug 2003Silverman David E.Method for treating morbid obesity
US2004003440828 Mar 200319 Feb 2004Majercak David ChristopherMethod of placing a tubular membrane on a structural frame
US2004005936830 Jul 200325 Mar 2004Asap Breatheassist Pty Ltd.Nasal cavity dilator
US200401070049 Jan 20033 Jun 2004Seedling Enterprises, LlcBariatric sleeve
US2004011703116 Jan 200317 Jun 2004Stack Richard S.Satiation devices and methods
US2004015833112 Mar 200312 Aug 2004Stack Richard S.Method and apparatus for modifying the exit orifice of a satiation pouch
US200401721414 Mar 20042 Sep 2004Stack Richard S.Satiation devices and methods
US200401721424 Mar 20042 Sep 2004Stack Richard S.Satiation devices and methods
US2004021382524 Apr 200328 Oct 2004Levy Mark M.Gastrointestinal bioreactor
US2004023022230 Jan 200418 Nov 2004Van Der Burg Erik J.System for left atrial appendage occlusion
US2004023635710 Jun 200425 Nov 2004Esophyx, Inc.Transoral endoscopic gastroesophageal flap valve restoration device, assembly, system and method
US2004026737821 Jun 200430 Dec 2004Gazi Bashir MussaSemi-stationary balloon in the gastric antrum provided with connecting an anchoring rod for inducing weight reduction in human beings
US2005003333127 Apr 200410 Feb 2005Polymorfix, Inc., C/O Medventure AssociatesPyloric valve obstructing devices and methods
US2005003333224 Sep 200310 Feb 2005Burnett Daniel R.Pyloric valve corking device and method
US2005003846013 Sep 200417 Feb 2005Swaminathan JayaramanOcclusive coil manufacture and delivery
US2005003847015 Aug 200317 Feb 2005Van Der Burg Erik J.System and method for delivering a left atrial appendage containment device
US20050043759 *14 Jul 200424 Feb 2005Nmt Medical, Inc.Tubular patent foramen ovale (PFO) closure device with catch system
US200500550399 Aug 200410 Mar 2005Polymorfix, Inc.Devices and methods for pyloric anchoring
US200500640099 Jun 200424 Mar 2005Global Gene Therapies, Inc.Implantable device for treating disease states and methods of using same
US2005009087322 Oct 200328 Apr 2005Imran Mir A.Gastrointestinal stimulation device
US2005009667323 Jul 20045 May 2005Stack Richard S.Devices and methods for retaining a gastro-esophageal implant
US2005014914230 Jan 20047 Jul 2005Starkebaum Warren L.Gastric stimulation responsive to sensing feedback
US200501926278 Apr 20051 Sep 2005Whisenant Brian K.Patent foramen ovale closure devices, delivery apparatus and related methods and systems
US2005019262914 Feb 20051 Sep 2005Usgi Medical Inc.Methods and apparatus for creating and regulating a gastric stoma
US2005027306031 May 20058 Dec 2005Mayo Foundation For Medical Education And ResearchObesity treatment and device
US2005028878621 Apr 200529 Dec 2005Nmt Medical, Inc.Closure device with hinges
US2006002027829 Aug 200526 Jan 2006Polymorfix, Inc.Gastric retaining devices and methods
US2006017869115 Dec 200510 Aug 2006Binmoeller Kenneth FMethods and devices to curb appetite and/or reduce food intake
US200602177637 Jun 200628 Sep 2006Ryan AbbottSystems and Methods for Treating Septal Defects
US2006025907418 Feb 200616 Nov 2006Brian KelleherMethods and devices for anchoring to soft tissue
US200602821078 May 200614 Dec 2006Kiyoshi HashibaIntragastric device for treating obesity
US200602937428 May 200628 Dec 2006Mitchell DannCuff and sleeve system for gastrointestinal bypass
US2007001626211 Apr 200618 Jan 2007Betastim, Ltd.Gi and pancreatic device for treating obesity and diabetes
US200700275482 Oct 20061 Feb 2007Levine Andy HAnti-obesity devices
US2007005659115 Sep 200515 Mar 2007Mcswain HughFallopian tube occlusion devices and methods
US2007008322416 Jun 200512 Apr 2007Hively Robert LGastric bariatric apparatus with selective inflation and safety features
US200701781605 Feb 20072 Aug 2007Baronova, Inc.Gastro-intestinal device and method for treating addiction
US2007019808214 Dec 200623 Aug 2007The Cleveland Clinic FoundationApparatus and method for treating a regurgitant valve
US2007023928421 Dec 200611 Oct 2007Skerven Gregory JCoiled intragastric member for treating obesity
US200702501325 Feb 200725 Oct 2007Baronova, Inc.Devices and methods for gastrointestinal stimulation
US200901187579 Jan 20097 May 2009Burnett Daniel RPyloric valve obstructing devices and methods
US200901187589 Jan 20097 May 2009Burnett Daniel RPyloric valve obstructing devices and methods
US2009017728829 Oct 20059 Jul 2009Pnn Medical S.A.Stent for Use in a Tubular Organ of a Body
US2009018235712 Jan 200916 Jul 2009Baronova, Inc.Device for intermittently obstructing a gastric opening and method of use
US2009018235812 Jan 200916 Jul 2009Baronova.Inc.Device for intermittently obstructing a gastric opening and method of use
US200901872009 Jan 200923 Jul 2009Daniel Rogers BurnettGastric retaining devices and methods
US200901872019 Jan 200923 Jul 2009Daniel Rogers BurnettGastric retaining devices and methods
US200901982105 Sep 20086 Aug 2009Baronova, Inc.Device for intermittently obstructing a gastric opening and method of use
US200902162621 May 200927 Aug 2009Burnett Daniel RGastric retaining devices and methods
US2009029948628 Jun 20073 Dec 2009Slimedics Ltd.Gastrointestinal Prostheses
DE4012642A120 Apr 199024 Oct 1991Wolf Gmbh RichardTherapy or surgical instrument - has pre-shaped balloons of different sizes inflated via endoscope etc.
WO1988000027A19 Jul 198614 Jan 1988Angelchik Jean PMethod for treatment of morbid obesity
WO1990000369A15 Jul 198925 Jan 1990Transpharm GroupA removable inflatable intragastrointestinal device for delivering beneficial agents
WO2000048672A122 Feb 200024 Aug 2000Knowlton Edward WStomach treatment apparatus and method
WO2002091961A117 May 200221 Nov 2002Wilson-Cook Medical, Inc.Intragastric device for treating obesity
WO2003017882A226 Aug 20026 Mar 2003Synecor, LlcSatiation devices and methods
WO2005009288A220 Jul 20043 Feb 2005Polymorfix, Inc.Pyloric valve obstructing devices and methods
WO2005104989A226 Apr 200510 Nov 2005Medtronic, Inc.Esophageal delivery system and method with position indexing
WO2006020370A225 Jul 200523 Feb 2006Baronova, Inc.Devices and methods for pyloric anchoring
WO2006135857A212 Jun 200621 Dec 2006Novalert, Inc.Method and apparatus for monitoring implants
WO2007027812A229 Aug 20068 Mar 2007Baronova, Inc.Gastric retaining devices and methods
WO2007092390A25 Feb 200716 Aug 2007Baronova, Inc.Devices and methods for gastrointestinal stimulation
WO2007092501A25 Feb 200716 Aug 2007Baronova, Inc.Gastro-intestinal device and method for treating addiction
WO2009033049A15 Sep 200812 Mar 2009Baronova, Inc.Device for intermittently obstructing a gastric opening and method of use
Non-Patent Citations
Reference
1Australian Patent Application No. 2004258968 filed Jul. 20, 2004 in the name of Baranova, Inc., Office Action mailed Feb. 10, 2011.
2Australian Patent Application No. 2004258968 filed Jul. 20, 2004 in the name of Baranova, Inc., Office Action mailed Jan. 11, 2010.
3Australian Patent Application No. 2005274132 filed Jul. 25, 2005 in the name of Baranova, Inc., Office Action mailed Mar. 22, 2010.
4Australian Patent Application No. 2006284801 filed Aug. 29, 2006 in the name of Baranova, Inc., Office Action mailed Oct. 16, 2009.
5Australian Patent Application No. 2007212404 filed Feb. 5, 2007 in the name of Baranova, Inc., Office Action mailed May 2, 2011.
6Australian Patent Application No. 2007212473 filed Feb. 5, 2007 in the name of Baranova, Inc., Office Action mailed Apr. 20, 2011.
7Canadian Patent Application No. 2,534,118 filed Jul. 20, 2004 in the name of Baranova, Inc., Notice of Allowance mailed Jan. 24, 2011.
8Canadian Patent Application No. 2,534,118 filed Jul. 20, 2004 in the name of Burnett et al., Office Action mailed Apr. 1, 2010.
9Canadian Patent Application No. 2,576,476 filed Jul. 25, 2005 in the name of Baranova, Inc., Office Action mailed Dec. 3, 2010.
10Canadian Patent Application No. 2,620,859 filed Aug. 29, 2006 in the name of Baranova, Inc., Notice of Allowance mailed Feb. 4, 2011.
11Canadian Patent Application No. 2,620,859 filed Aug. 29, 2006 in the name of Burnett et al., Office Action mailed Apr. 20, 2010.
12European Patent Application No. 04778818.7 filed Jul. 20, 2004 in the name of Burnett et al., Office Action mailed Oct. 5, 2009.
13European Patent Application No. 05774631.5 filed Jul. 25, 2005 in the name of Baranova, Inc., Office Action mailed Mar. 25, 2011.
14European Patent Application No. 05774631.5 filed Jul. 25, 2005 in the name of Burnett et al., Office Action mailed Mar. 16, 2010.
15European Patent Application No. 05774631.5 filed Jul. 25, 2005 in the name of Burnett et al., Supplementary Partial European Search Report and Opinion mailed Dec. 1, 2009.
16European Patent Application No. 07763667.8 filed Feb. 5, 2007 in the name of Burnett, Office Action mailed Apr. 12, 2010.
17European Patent Application No. 07763667.8 filed Feb. 5, 2007 in the name of Burnett, Search Report and Opinion mailed Dec. 23, 2009.
18International Patent Application No. PCT/US2004/023470 filed Jul. 20, 2004 in the name of Polymorfix, Inc., International Search Report and Written Opinion mailed May 27, 2005.
19International Patent Application No. PCT/US2005/026370 filed Jul. 25, 2005 in the name of Baronova, Inc., International Search Report and Written Opinion mailed Sep. 30, 2008.
20International Patent Application No. PCT/US2006/033923 filed Aug. 29, 2006 in the name of Baronova, Inc., International Search Report and Written Opinion mailed Jan. 18, 2008.
21International Patent Application No. PCT/US2007/003052 filed Feb. 5, 2007 in the name of Baronova, Inc., International Search Report and Written Opinion mailed Nov. 19, 2007.
22International Patent Application No. PCT/US2007/003260 filed Feb. 5, 2007 in the name of Baronova, Inc., International Search Report and Written Opinion mailed Sep. 26, 2008.
23International Patent Application No. PCT/US2008/075439 filed Sep. 5, 2008 in the name of Baronova, Inc., International Search Report and Written Opinion mailed Nov. 10, 2008.
24Japanese Patent Application No. 2006-521910 filed Jul. 20, 2004 in the name of Polymorfix, Inc., Office Action mailed Mar. 9, 2010.
25Japanese Patent Application No. 2007-525638 filed Jul. 25, 2005 in the name of Baranova, Inc., Office Action mailed Jan. 4, 2011.
26Japanese Patent Application No. 2008-529243 filed Aug. 29, 2006 in the name of Baranova, Inc., Office Action mailed May 17, 2011.
27U.S. Appl. No. 10/671,191, filed Sep. 24, 2003 in the name of Burnett, Final Office Action mailed May 5, 2005.
28U.S. Appl. No. 10/671,191, filed Sep. 24, 2003 in the name of Burnett, Non-final Office Action mailed Dec. 15, 2004.
29U.S. Appl. No. 10/671,191, filed Sep. 24, 2003 in the name of Burnett, Notice of Allowance mailed Sep. 13, 2005.
30U.S. Appl. No. 10/833,950, filed Apr. 27, 2004 in the name of Burnett et al., final Office Action mailed Jan. 28, 2010.
31U.S. Appl. No. 10/833,950, filed Apr. 27, 2004 in the name of Burnett et al., Non-final Office Action mailed Apr. 15, 2009.
32U.S. Appl. No. 10/833,950, filed Apr. 27, 2004 in the name of Burnett et al., Non-final Office Action mailed Nov. 17, 2010.
33U.S. Appl. No. 10/915,716, filed Aug. 9, 2004 in the name of Burnett et al., Final Office Action mailed Dec. 29, 2010.
34U.S. Appl. No. 10/915,716, filed Aug. 9, 2004 in the name of Burnett et al., Final Office Action mailed Mar. 19, 2009.
35U.S. Appl. No. 10/915,716, filed Aug. 9, 2004 in the name of Burnett et al., Non-final Office Action mailed Dec. 8, 2009.
36U.S. Appl. No. 10/915,716, filed Aug. 9, 2004 in the name of Burnett et al., Non-final Office Action mailed May 29, 2008.
37U.S. Appl. No. 11/215,430, filed Aug. 29, 2005 in the name of Burnett et al., Final Office Action mailed May 28, 2008.
38U.S. Appl. No. 11/215,430, filed Aug. 29, 2005 in the name of Burnett et al., Non-final Office Action mailed Feb. 13, 2009.
39U.S. Appl. No. 11/215,430, filed Aug. 29, 2005 in the name of Burnett et al., Non-final Office Action mailed Mar. 23, 2011.
40U.S. Appl. No. 11/215,430, filed Aug. 29, 2005 in the name of Burnett et al., Non-final Office Action mailed Mar. 8, 2007.
41U.S. Appl. No. 11/702,840, filed Feb. 5, 2007 in the name of Burnett et al., non-final Office Action mailed Feb. 4, 2010.
42U.S. Appl. No. 11/702,840, filed Feb. 5, 2007 in the name of Burnett et al., Non-final Office Action mailed May 20, 2011.
43U.S. Appl. No. 11/702,840, filed Feb. 5, 2007 in the name of Burnett, Final Office Action mailed Oct. 27, 2010.
44U.S. Appl. No. 12/351,644, filed Jan. 9, 2009 in the name of Burnett et al., Non-final Office Action mailed Mar. 24, 2011.
45U.S. Appl. No. 12/351,665, filed Jan. 9, 2009 in the name of Burnett et al., Non-final Office Action mailed Mar. 24, 2011.
46U.S. Appl. No. 12/351,686, filed Jan. 9, 2009 in the name of Burnett et al., final Office Action mailed Mar. 11, 2011.
47U.S. Appl. No. 12/351,686, filed Jan. 9, 2009 in the name of Burnett et al., non-final Office Action mailed Jul. 8, 2010.
48U.S. Appl. No. 12/351,705, filed Jan. 9, 2009 in the name of Burnett et al., final Office Action mailed Jun. 9, 2011.
49U.S. Appl. No. 12/351,705, filed Jan. 9, 2009 in the name of Burnett et al., Non-final Office Action mailed Sep. 29, 2010.
50U.S. Appl. No. 12/352,497, filed Jan. 12, 2009 in the name of Burnett et al., Non-final Office Action mailed Dec. 23, 2010.
51U.S. Appl. No. 12/434,594, filed May 1, 2009 in the name of Burnett et al., Non-final Office Action mailed Mar. 24, 2011.
Legal Events
DateCodeEventDescription
6 Jul 2007ASAssignment
Owner name: BARONOVA, INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BURNETT, DANIEL R;REEL/FRAME:019523/0235
Effective date: 20070410